CAR T-Cell Production Using Nonviral Approaches

J 2021

CAR T-Cell Production Using Nonviral Approaches

LUKJANOV, Viktor, Irena KOUTNÁ a Pavel ŠIMARA

Základní údaje

Originální název

CAR T-Cell Production Using Nonviral Approaches

Název česky

Výroba CAR T-lymfocytů pomocí nevirových metod

Autoři

LUKJANOV, Viktor (203 Česká republika, domácí), Irena KOUTNÁ (203 Česká republika, domácí) a Pavel ŠIMARA (203 Česká republika, garant, domácí)

Vydání

Journal of Immunology Research, London, Hindawi, 2021, 2314-8861

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Hindawi

Impakt faktor

Impact factor: 4.493

Kód RIV

RIV/00216224:14110/21:00120099

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1155/2021/6644685

UT WoS

000637765000002

Klíčová slova česky

CAR T-lymfocyty; PiggyBac

Klíčová slova anglicky

CAR T-cells; PiggyBac

Štítky

14110517, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 6. 2021 08:33, Mgr. Tereza Miškechová

Anotace

V originále

Chimeric antigen receptor T-cells (CAR T-cells) represent a novel and promising approach in cancer immunotherapy. According to the World Health Organization (WHO), the number of oncological patients is steadily growing in developed countries despite immense progress in oncological treatments, and the prognosis of individual patients is still relatively poor. Exceptional results have been recorded for CAR T-cell therapy in patients suffering from B-cell malignancies. This success opens up the possibility of using the same approach for other types of cancers. To date, the most common method for CAR T-cell generation is the use of viral vectors. However, dealing with virus-derived vectors brings possible obstacles in the CAR T-cell manufacturing process owing to strict regulations and high cost demands. Alternative approaches may facilitate further development and the transfer of the method to clinical practice. The most promising substitutes for virus-derived vectors are transposon-derived vectors, most commonly sleeping beauty, which offer great coding capability and a safe integration profile while maintaining a relatively low production cost. This review is aimed at summarizing the state of the art of nonviral approaches in CAR T-cell generation, with a unique perspective on the conditions in clinical applications and current Good Manufacturing Practice. If CAR T-cell therapy is to be routinely used in medical practice, the manufacturing cost and complexity need to be as low as possible, and transposon-based vectors seem to meet these criteria better than viral-based vectors.

Návaznosti

NV19-08-00147, projekt VaV

Název: Pre-klinická validace cGMP produkce CAR T-lymfocytů pro léčbu solidních tumorů

Investor: Ministerstvo zdravotnictví ČR, Pre-klinická validace cGMP produkce CAR T-lymfocytů pro léčbu solidních tumorů

Citovat

LUKJANOV, Viktor, Irena KOUTNÁ a Pavel ŠIMARA. CAR T-Cell Production Using Nonviral Approaches. Journal of Immunology Research. London: Hindawi, 2021, roč. 2021, Mar 27, s. 1-9. ISSN 2314-8861. Dostupné z: https://dx.doi.org/10.1155/2021/6644685.

@article{1769838,
   author = {Lukjanov, Viktor and Koutná, Irena and Šimara, Pavel},
   article_location = {London},
   article_number = {Mar 27},
   doi = {http://dx.doi.org/10.1155/2021/6644685},
   keywords = {CAR T-cells; PiggyBac},
   language = {eng},
   issn = {2314-8861},
   journal = {Journal of Immunology Research},
   title = {CAR T-Cell Production Using Nonviral Approaches},
   url = {https://www.hindawi.com/journals/jir/2021/6644685/},
   volume = {2021},
   year = {2021}
}

TY  - JOUR
ID  - 1769838
AU  - Lukjanov, Viktor - Koutná, Irena - Šimara, Pavel
PY  - 2021
TI  - CAR T-Cell Production Using Nonviral Approaches
JF  - Journal of Immunology Research
VL  - 2021
IS  - Mar 27
SP  - 1-9
EP  - 1-9
PB  - Hindawi
SN  - 23148861
KW  - CAR T-cells
KW  - PiggyBac
UR  - https://www.hindawi.com/journals/jir/2021/6644685/
N2  - Chimeric antigen receptor T-cells (CAR T-cells) represent a novel and promising approach in cancer immunotherapy. According to the World Health Organization (WHO), the number of oncological patients is steadily growing in developed countries despite immense progress in oncological treatments, and the prognosis of individual patients is still relatively poor. Exceptional results have been recorded for CAR T-cell therapy in patients suffering from B-cell malignancies. This success opens up the possibility of using the same approach for other types of cancers. To date, the most common method for CAR T-cell generation is the use of viral vectors. However, dealing with virus-derived vectors brings possible obstacles in the CAR T-cell manufacturing process owing to strict regulations and high cost demands. Alternative approaches may facilitate further development and the transfer of the method to clinical practice. The most promising substitutes for virus-derived vectors are transposon-derived vectors, most commonly sleeping beauty, which offer great coding capability and a safe integration profile while maintaining a relatively low production cost. This review is aimed at summarizing the state of the art of nonviral approaches in CAR T-cell generation, with a unique perspective on the conditions in clinical applications and current Good Manufacturing Practice. If CAR T-cell therapy is to be routinely used in medical practice, the manufacturing cost and complexity need to be as low as possible, and transposon-based vectors seem to meet these criteria better than viral-based vectors.
ER  -

LUKJANOV, Viktor, Irena KOUTNÁ a Pavel ŠIMARA. CAR T-Cell Production Using Nonviral Approaches. \textit{Journal of Immunology Research}. London: Hindawi, 2021, roč.~2021, Mar 27, s.~1-9. ISSN~2314-8861. Dostupné z: https://dx.doi.org/10.1155/2021/6644685.

Podrobný výpis o publikaci